$BIIB Biogen Inc. (NASDAQ:BIIB) – Research analysts at Wedbush dropped their Q4 2021 earnings per share (EPS) estimates for shares of Biogen in a research note issued to investors on Monday, July 12th. Wedbush analyst L. Chico now expects that the biotechnology company will post earnings of $3.48 per share for the quarter, down from their prior forecast of $3.59. Wedbush has a “Neutral” rating and a $245.00 price target on the stock.